| 08/05 | Goldman Sachs Adjusts Price Target for Vertex Pharmaceuticals to $389 From $368, Mainta.. | MT |
| 08/05 | HC Wainwright Raises Vertex Pharmaceuticals Price Target to $300 From $275, Maintains B.. | MT |
| 08/05 | BioNTech, Genmab Expand Cancer Treatment Collaboration to Address Malignant Solid Tumor.. | MT |
| 08/05 | Barclays Adjusts Price Target on Vertex Pharmaceuticals to $307 From $291, Reiterates O.. | MT |
| 08/05 | RBC Raises Price Target on Vertex Pharmaceuticals to $278 From $269, Maintains Sector P.. | MT |
| 08/05 | Genmab, BioNTech Expand Cancer Therapy Collaboration | MT |
| 08/05 | Genmab, BioNTech Expand Research Partnership for Cancer Treatments | DJ |
| 08/04 | TRANSCRIPT : Vertex Pharmaceuticals Incorporated, Q2 2022 Earnings Call, Aug 04, 2022 | CI |
| 08/04 | Vertex Pharmaceuticals Reports Higher Q2 Adjusted Profit, Revenue; Lifts 2022 Product R.. | MT |
| 08/04 | Earnings Flash (VRTX) VERTEX PHARMACEUTICALS INCORPORATED Reports Q2 EPS $3.60 | MT |
| 08/04 | Vertex Pharmaceuticals Incorporated Reports Earnings Results for the Second Quarter and.. | CI |
| 08/04 | Vertex Pharmaceuticals Incorporated Reports Unaudited Intangible Asset Impairment Charg.. | CI |
| 08/04 | EARNINGS REACTION HISTORY : Vertex Pharmaceuticals, 50.0% Follow-Through Indicator, 2.4% S.. | MT |
| 08/04 | Goldman Sachs Increases Regeneron Pharmaceuticals' Price Target to $796 From $790, Main.. | MT |
| 08/04 | UBS Adjusts Gilead Sciences Price Target to $65 From $63, Maintains Neutral Rating | MT |
| 08/04 | Morgan Stanley Raises Regeneron Pharmaceuticals' Price Target to $625 From $619, Mainta.. | MT |
| 08/04 | Gilead Sciences to Buy UK Biotech Firm MiroBio for $405 Million | MT |
| 08/04 | RBC Raises Price Target on Regeneron Pharmaceuticals to $647 From $640, Maintains Secto.. | MT |
| 08/04 | Gilead Sciences, Inc. entered into a definitive agreement to acquire MiroBio Ltd from S.. | CI |
| 08/03 | Wall Street rises on tech, earnings boost as recession fears ease | RE |
| 08/03 | European ADRs Nudge Higher in Wednesday Trading | MT |
| 08/03 | Regeneron Pharmaceuticals Up Over 7%, on Pace for Largest Percent Increase Since June 2.. | DJ |
| 08/03 | Gilead Sciences Up Over 5%, on Pace for Largest Percent Increase Since January 2021 -- .. | DJ |
| 08/03 | US STOCKS-Strong earnings lift Wall Street ahead of services activity data | RE |
| 08/03 | TRANSCRIPT : Regeneron Pharmaceuticals, Inc., Q2 2022 Earnings Call, Aug 03, 2022 | CI |
| 08/03 | Regeneron Pharmaceuticals Q2 Adjusted Earnings, Revenue Decline | MT |
| 08/03 | Earnings Flash (REGN) REGENERON PHARMACEUTICALS Posts Q2 Revenue $2.86B | MT |
| 08/03 | Earnings Flash (REGN) REGENERON PHARMACEUTICALS Posts Q2 EPS $9.77 | MT |
| 08/03 | Regeneron quarterly profit slips as COVID antibody sales dry up | RE |
| 08/03 | Regeneron Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six.. | CI |
| 08/03 | Regeneron Pharmaceuticals, Inc. Announces Encouraging Initial Data from Phase 1/2 Trial.. | CI |
| 08/02 | Hong Kong Allows Sinovac Shots For Infants | MT |
| 08/02 | Gilead Sciences Updates Fiscal Year Outlook Following 2Q Results | DJ |
| 08/02 | INSIDER SELL : Regeneron Pharmaceuticals | MT |
| 08/02 | INSIDER SELL : Vertex Pharmaceuticals | MT |
| 08/02 | Gilead Sciences Posts Slightly Higher 2Q Sales | DJ |
| 08/02 | Gilead quarterly profit falls as COVID antiviral sales decrease | RE |
| 08/02 | TRANSCRIPT : Gilead Sciences, Inc., Q2 2022 Earnings Call, Aug 02, 2022 | CI |
| 08/02 | Gilead Sciences Q2 Adjusted EPS Drop While Revenue Gains; Company Boosts 2022 Outlook | MT |
| 08/02 | Gilead Sciences, Inc. Declares Quarterly Cash Dividend for the Third Quarter of 2022, P.. | CI |
| 08/02 | GUIDANCE : (GILD) GILEAD SCIENCES Sees Fiscal Year 2022 EPS Range $6.35 - $6.75 | MT |
| 08/02 | Earnings Flash (GILD) GILEAD SCIENCES Reports Q2 Revenue $6.26B | MT |
| 08/02 | Earnings Flash (GILD) GILEAD SCIENCES Posts Q2 EPS $1.58 | MT |
| 08/02 | Gilead Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months En.. | CI |
| 08/02 | EARNINGS REACTION HISTORY : Gilead Sciences, 63.6% Follow-Through Indicator, 3.0% Sensitiv.. | MT |
| 08/02 | Pfizer Seeks Extended Swiss Approval For COVID-19 Vaccine to Cover Omicron Protection | MT |
| 07/29 | SVB Securities Adjusts BioNTech's Price Target to $224 from $223, Keeps Outperform Rati.. | MT |
| 07/29 | UBS Adjusts Wuxi Apptec's Price Target to HK$175 From HK$173, Keeps at Buy | MT |
| 07/28 | Gilead Sciences, Inc. Announces Executive Changes | CI |
| 07/28 | Gilead Sciences Says Biktarvy Treatment Shows Efficacy in Patients With HIV/Hepatitis B.. | MT |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
